Createrna Science and Technology

Based in Wuhan, China, and founded in 2013, Createrna Science and Technology is a biopharmaceutical company under Wuhan Qirui Technology Development. As of 2023, it has over 240 employees and over 80% of whom are research and development personnel. The company has R&D centers in Wuhan and Shanghai. In September 2021, it was rewarded as "Outstanding High-tech Enterprise".

In April 2023, the translational medicine research center was established. In June 2023, Createrna Science and Technology raised CNY 500 million in series A funding led by Lilly Asia Ventures. Yaning Wang, the CEO of the company, has 20 years of experience in new drug development and regulation, and is a standing member of the Chinese Committee of Quantitative Pharmacology. It has more than 300 partners, such as Joinn, Beijing University and Wuxi AppTec.

The company has developed a full-process new drug research and development system from Proof of concept, candidate compound screening, and pre-clinical pharmaceutical development to clinical research. It has built a pharmaceutical information platform and has the ability of early Proof of concept of the project. In addition, the company has established a variety of screening and evaluation models for biological activity screening and cell efficacy research in vitro and an in vivo model-building platform, which has completed the construction of multiple disease models, including cough, fibrosis, kidney disease, and other related diseases. It has several drugs under research for rheumatoid arthritis, psoriasis, inflammatory bowel disease, etc.